This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Metyrapone test

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is a test for Cushing's syndrome that is now rarely used.

Metyrapone inhibits 11-beta-hydroxylation in the adrenal cortex and hence cortisol and corticosterone synthesis. A low corticosteroid level causes increased ACTH secretion and therefore adrenal stimulation and further 11-deoxycortisol production (since cortisol production is blocked). The metabolites of 11-deoxycortisol (17-hydroxy and 17-ketogenic steroids) are excreted in the urine.

Interpretation of test results:

  • normal individuals - increased levels of metabolites
  • adrenal hyperplasia - Cushing's disease - higher levels of metabolites
  • if Cushing's syndrome is due to ectopic ACTH production, an adrenal adenoma, or adrenal carcinoma, then there is characteristically little or no increased levels of metabolites after metyrapone
  • reduced responses to metyrapone may be seen in:
    • hypopituitarism
    • primary thyrotoxicosis
    • pregnancy (but metyrapone is contraindicated in these patients)
    • some patients taking phenytoin or the oral contraceptive pill

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.